Video
Author(s):
Julien Taieb, MD, head of the gastroenterology and gastrointestinal oncology department of the Georges Pompidou European Hospital, Paris Descartes University, discusses sidedness in metastatic colon cancer.
Julien Taieb, MD, head of the gastroenterology and gastrointestinal oncology department of the Georges Pompidou European Hospital, Paris Descartes University, discusses sidedness in metastatic colon cancer.
Taieb states that disease-free survival with no recurrence is not impacted by sidedness. Conversely, if a patient relapses, the survival after relapse is clearly impacted by sidedness with right-sided tumors having a poorer prognosis.
For patients who are BRAF and KRAS mutant, it seems that having a right-sided tumor is a good prognostic factor, Taieb adds.